These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7010448)

  • 1. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
    Ehrman ML; Jaffe EA
    Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
    Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
    Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
    Hawiger J; Parkinson S; Timmons S
    Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of platelet aggregation and elevation of cyclic-AMP levels in platelets by 13,14-dehydro PGI2 methyl ester.
    Malmsten C; Claesson HE; Fried J
    Prostaglandins Med; 1980 Jun; 4(6):453-63. PubMed ID: 6251494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of age, sex, and the use of oral contraceptives on the inhibitory effects of endothelial cells and PGI2 (prostacyclin) on platelet function.
    Nordøy A; Svensson B; Haycraft D; Hoak JC; Wiebe D
    Scand J Haematol; 1978 Sep; 21(3):177-87. PubMed ID: 362511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sub-aggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation.
    Buttrick PM; Forscher CA; Sussman II; Mueller HS
    Am Heart J; 1985 Jun; 109(6):1258-63. PubMed ID: 2988323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dipyridamole on prostaglandin generation by human platelets and vessel walls.
    Mehta J; Mehta P; Hay D
    Prostaglandins; 1982 Dec; 24(6):751-61. PubMed ID: 6820166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N
    Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
    Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
    Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A platelet procoagulant activity associated with platelet shape change.
    Ehrman M; Toth E; Frojmovic M
    J Lab Clin Med; 1978 Sep; 92(3):393-401. PubMed ID: 681825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandins and platelet aggregation.
    Smith JB
    Acta Med Scand Suppl; 1981; 651():91-9. PubMed ID: 7034481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated plateletes.
    Rao GH; Reddy KR; White JG
    Prostaglandins Med; 1980 Jun; 4(6):385-97. PubMed ID: 6251492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
    Pedvis LG; Wong T; Frojmovic MM
    Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.
    Weithmann KU
    Gen Pharmacol; 1983; 14(1):161-2. PubMed ID: 6298055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.